DNA גידולי חופשי כמנבא לסרטן פולשני של דרכי השתן
ממצאי מחקר מדגימים את החשיבות של ctDNA כסמן ביולוגי לסיוע בבחירת מטופלים לכימותרפיה ניאואדג'ובנטית לפני כריתת כליה ושופכן

במחקר שהתפרסם בכתב העת European Urology בחנו האם הימצאות של DNA ממקור גידול חופשי בפלסמה יכול לשמש בסמן

Such a pleasure to have the chance to write and publish this article with Matt Galsky and Dr. John Sfakianos.
Novel bladder-sparing approaches for optimal candidates with MIBC are an important alternative to radical cystectomy.
Tumor-informed ctDNA and mpMRI using VI-RADS score

What better way to pick me up than confirming my remission will continue on?

CtDNA tests for my mutation didn’t exist during my first remission. This helps me both physically and mentally.

Improving cancer care keeps me hopeful.

#thankscancer #melanoma #mentalhealth

とりあえず全大腸外科民に拡散しといて欲しいんですけど、周術期にRAS/RAFとMSIは測っといて欲しいんだわ。いやマジでホンマに。ctDNA時代でも特にBRAFは再発ハイリスクだから。
なんなら術前に内科で出して欲しいんよ、いやマジでホンマに。

A tiebreaker in CDK after CDK #postMONARCH and of course, can't go through any oncology conference today without the hot topic of #ctDNA . #bcsm #ASCO24

Haystack MRD™ was purpose-built to detect circulating tumor DNA ( #ctDNA —fragments of DNA that are released by tumor cells into the bloodstream) from residual cancer cells after surgery. Learn about the benefits of MRD testing at hubs.la/Q02tbV_x0 #MRD

More informative work from Faden Lab on HPV ctDNA for OPSCC. Detecting it certainly predicts recurrence post-treatment irrespective of therapy modality; however, limitations in both NPV and actionability of positive results still hinder its utility presently.

If you biopsy H+N cancer do you see the whole genetic landscape? Can you see this better in a ctDNA liquid biopsy and track it over time?🤷🏼‍♂️ Published some interesting pilot data👇🏼 InHANSE RESEARCH Medical and Dental Research (UoB) BAOMS Science and Innovation at Cancer Research UK Paul Nankivell

frontiersin.org/journals/oncol…

ctDNA dynamics in adv KRASG12C+ NSCLC on sotorasib JTO & JTO CRR:

- Pre-Tx ctDNA+ in 76% (50/66) pts
- ctDNA+ pts had ⬇️PFS (HR 2.13 p=0.031) ⬇️OS(HR 2.61 p=0.017)
- ⬇️ctDNA at 28d assoc w ⬆️DCR

So far, ctDNA appears prognostic
Anne-Marie Dingemans OncoAlert

jto.org/article/S1556-…

🧬ctDNA during neoadjuvant chemotherapy in breast cancer
The Breast Online ESMO - Eur. Oncology

✅Larger decrease in ctDNA levels, pCR⬆️
✅Interval on-treatment ctDNA is predictive for the response
✅Early change of ctDNA (decrease vs increase) is associated with recurrence-free survival

Reviewing 628 anal cancer cases, ctDNA shows promise as a management biomarker. Sensitivity ranges from 82-100%. Decreasing ctDNA post-treatment correlates with lower recurrence risk. #AnalCancer #ctDNA #CancerBiomarkers #OncologyResearch

The rise of highly sensitive liquid biopsy that utilizes next generation sequencing and PCR to detect few genome!!! of ctDNA (Circulating tumor DNA) from blood plasma authorized in '20 in order to put patients on early cancer program= 💰💰💰for Big Pharma
twitter.com/sandoly/status…

🔎 As the the first study of its kind to use a tumor-informed ctDNA assay in the US, the BESPOKE study utilized ctDNA-based MRD detection to inform adjuvant #chemotherapy in #ColorectalCancer .

Learn more from Dr. Pashtoon Kasi MD, MS:

buff.ly/4b2KSd7

#ColonCancer

Dr. Lynn Fynn-derella🐭 The rise of highly sensitive liquid biopsy that utilizes next generation sequencing and PCR to detect few genome!!! of ctDNA (Circulating tumor DNA) from blood plasma authorized in '20 in order to put patients on early cancer program= 💰💰💰for Big Pharma
twitter.com/sandoly/status…

April Issue: Circulating Tumor DNA ( #ctDNA ) in the Immediate Postoperative Setting

rdcu.be/dFrzw

Nita Ahuja

Circulating biomarkers to monitor and guide Tx strategy for MBC. The promises of ctDNA by François-Clément Bidard from Seoul at GBCC 2024. Institut Curie Unicancer EORTC Breast Cancer Group BIG against BC

Baseline ctDNA based hyperselection identified optimal candidates for panitumumab + mFOLFOX in mCRC. Primary tumor location only serves as surrogate predictor of the anti-EGFR benefit. 🧬
See our Bulletin for more:

This review underscores the potential of plasma circulating tumor #HPV DNA ( #ctDNA ) as a #liquidbiomarker for surveillance of HPV-related #oropharyngealcancer in veterans.
Online：oaepublish.com/articles/2394-…
PDF：f.oaes.cc/xmlpdf/6639920…

肺癌でもctDNAは予後予測因子。でもKRAS G12Cなら良いが肺癌一般となるとドライバー遺伝子の種類が多い上に、点変異ではなく融合遺伝子なども多いから処理が若干複雑になるのかも？／JTO jto.org/article/S1556-…

What are the most significant developments in targeted therapies and liquid biopsies in recent years? Dr. Bartlett of AHN discusses updates in genomic testing for cancer patients with Targeted Oncology: bit.ly/3TUymFx #ctDNA #LiquidBiopsy #CancerResearch #CancerPatient